Stephen J. Russell MD PhD, Founder, Director, CEO & President
Dr Russell is the CEO of Vyriad. He is also the Richard O Jacobson Professor of Molecular Medicine at Mayo Clinic and Vice President of the American Society of Gene and Cell Therapy. He obtained his MD from the University of Edinburgh in 1982 and since that time has relentlessly pursued the goal of effective oncolytic virotherapy. He specialized clinically in hematology, then undertook his PhD training at the Royal Marsden hospital where he was the first to engineer both retroviral and parvoviral vectors to deliver interleukin genes for cancer immunotherapy. He then moved to Cambridge, England where he led a research team in the MRC Laboratory for Molecular Biology, developed a novel method for antibody affinity maturation using phage display libraries, pioneered the display antibody domains on retroviral vector particles and on recombinant measles viruses, and founded Cambridge Genetics, a biotechnology/drug discovery company. In 1998 he moved to Mayo Clinic where he founded the Department of Molecular Medicine, built a comprehensive oncolytic virotherapy program, developed innovative engineering approaches for targeting, arming and noninvasively monitoring OV infections, and orchestrated the GMP manufacture, preclinical pharmacological/toxicological testing, IND filing and clinical translation of a number of oncolytic Measles and Vesicular stomatitis viruses for several different cancer indications. He cofounded two oncolytic virotherapy companies which merged in 2015, thereby establishing Vyriad as the first multi-platform OV company.
Glen Barber PhD, Founder and Director
Dr. Barber is presently Chair and Professor of the Department of Cell Biology at the University of Miami Miller School of Medicine, Florida, as well as Associate Director for Basic Research at the University of Miami’s Sylvester Comprehensive Cancer Center (SCCC). He received his PhD from the University of London and Porton Down and conducted post-doctoral research at the University of Washington, Seattle and the University of Tokyo, Japan. He became Assistant Professor in the Department of Microbiology and Immunology and Winship Cancer Center at Emory University School of Medicine, Atlanta, prior to joining the University of Miami in 1999. Dr. Barber is a leader in the field of oncolytic viral therapies and has pioneered several discoveries related to understanding mechanisms of host defense and innate immunity.
Jim Hannon, Chief Financial Officer
Mr. Hannon is an experienced senior executive with extensive general and financial management experience in business operations, acquisition, divestiture and capital structuring. Industry experience includes biotechnology, biomedical, printing, manufacturing, distribution and alternative energies. Mr. Hannon received his Bachelor of Arts degree in Management and Accounting from the University of St. Thomas in 1973 and Masters of Science in Management from the Stanford Sloan Graduate School of Business in 1984. Mr. Hannon is also the Private Equity Manager for Quinstar Investment Partners.
Alice S. Bexon, MD, Chief Medical Officer
Dr. Bexon brings to Vyriad more than 20 years of management experience in clinical development of biopharmaceuticals, including management of multi-site clinical trials and FDA approval of lead assets. Prior to joining Vyriad, Dr. Bexon founded Bexon Clinical Consulting, which provides clinical development support to the pharma and biotech industries. Previously, Dr. Bexon was Vice President of Clinical Development of Idera Pharmaceuticals, from 2007-2009. From 2001-2006, she held a number of positions of increasing responsibility at Roche Oncology, including serving as a key member of the clinical development and life cycle team responsible for Xeloda®. Dr. Bexon earned her medical degree from Bristol University Medical School in the United Kingdom and her oncology diploma at the Institut Gustave Roussy in France.
Shruthi Naik PhD, Founder and VP, Comparative Oncology
Dr. Naik is a researcher in the Department of Molecular Medicine at Mayo Clinic. She has extensive knowledge and experience developing VSV based technologies, having both designed and developed products currently in clinical development. Dr. Naik has successfully implemented and coordinated innovative and collaborative approaches to facilitate clinical translation of novel cancer therapies, building strong multi-institutional teams and infrastructures to optimize the process of clinical drug development. She holds degrees in Molecular Biology and Economics & Finance, and received her PhD from Mayo Graduate School.
Kah Whye Peng PhD, Founder and Chief Technology Officer
Dr. Peng is Professor of Oncology and Director of the Pharmacology and Toxicology Laboratory in the Department of Molecular Medicine at Mayo Clinic. She is a Council Member of the International Society of Cell and Gene Therapy and serves on NIH grant review panels. She obtained her BSc degree (First Class Honors) in Zoology from the National University of Singapore and her PhD degree in Gene Therapy from the University of Cambridge, United Kingdom. Her research focuses on the development of new technologies that can be applied for targeting, monitoring and enhancing the potency of novel cell, gene and virus-based anticancer therapies, and to advance the most promising technologies to clinical testing.